JMP Securities Increases Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $6.00

Taysha Gene Therapies (NASDAQ:TSHA - Free Report) had its price objective lifted by JMP Securities from $5.00 to $6.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a market outperform rating on the stock.

Several other research analysts have also recently weighed in on the stock. Citigroup reiterated an "outperform" rating on shares of Taysha Gene Therapies in a report on Thursday. Canaccord Genuity Group raised their price target on shares of Taysha Gene Therapies from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, May 16th. Chardan Capital raised their price target on shares of Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a "buy" rating in a report on Thursday. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Monday, April 28th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies currently has an average rating of "Buy" and a consensus target price of $7.00.

Taysha Gene Therapies Price Performance

TSHA stock traded down $0.04 on Thursday, hitting $2.71. 5,622,850 shares of the company's stock traded hands, compared to its average volume of 3,008,932. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The stock has a market cap of $581.73 million, a price-to-earnings ratio of 4.30 and a beta of 0.90. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $4.32. The stock has a fifty day moving average of $1.92 and a 200-day moving average of $1.91.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The firm had revenue of $2.30 million for the quarter, compared to the consensus estimate of $1.48 million. During the same quarter last year, the firm posted ($0.10) EPS. On average, analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Taysha Gene Therapies

Hedge funds have recently made changes to their positions in the stock. Granahan Investment Management LLC lifted its position in Taysha Gene Therapies by 0.3% during the first quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company's stock worth $2,281,000 after buying an additional 4,412 shares in the last quarter. Hsbc Holdings PLC boosted its position in shares of Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock worth $36,000 after acquiring an additional 8,076 shares in the last quarter. Virtus ETF Advisers LLC lifted its holdings in shares of Taysha Gene Therapies by 43.0% in the 4th quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company's stock valued at $55,000 after purchasing an additional 9,494 shares during the last quarter. Geode Capital Management LLC raised its stake in Taysha Gene Therapies by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock valued at $6,182,000 after acquiring an additional 9,591 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock worth $820,000 after purchasing an additional 11,390 shares during the period. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.